• OFID 2018:5 (Suppl 1) • Poster Abstracts CLSI M100 MIC breakpoints. Clinically relevant, non-duplicate, isolates cultured from patients with SSSIs in 6 countries in LA in 2017 were tested by the AWARE Surveillance Program central laboratory (IHMA). In total, 1,435 non-duplicate isolates of MSSA, MRSA, β-hemolytic streptococci, and Enterobacteriaceae were tested: Argentina (n = 349/24.3% of all isolates tested), Brazil (114/7.9%), Chile (153/10.7%), Columbia (175/12.2%), Mexico (339/23.6%), and Venezuela (305/21.3%).
Conclusion. Overall, 100% of MSSA and 95.1% of MRSA from LA were susceptible to CPT (MIC ≤1 µg/mL); 19 isolates of MRSA were CPT-intermediate (MIC 2 µg/mL) with 17 of the 19 isolates being from Chile; no CPT-resistant MRSA were observed. All β-hemolytic streptococci and 86.6% of ESBL-negative Enterobacteriaceae were also susceptible to CPT. CPT continues to demonstrate potent in vitro activity against clinically relevant pathogens associated with SSSIs for patients in LA.
Disclosures Methods. Two multicenter, double-blind, double-dummy trials of adults with ABSSSI patients randomized 1:1 to receive either DLX monotherapy or VAN 15 mg/ kg (actual body weight) with AZ for 5-14 days. Study 302 used DLX 300 mg BID IV only; study 303 used DLX 300 mg BID IV for 3 days with a mandatory blinded switch to DLX 450 mg oral BID. Key endpoints were objective response at 48-72 hours with ≥20% reduction in lesion size; and Investigator assessment of outcome based on resolution of signs and symptoms at Follow-up (FU day 14) and Late Follow-up (LFU day 21-28).
Results. In the two studies, 488 CV patients were randomized in United States, Europe, Latin America and Asia. 57% were male with mean age 59 years. Average erythema area at baseline was 446 cm 2 . 58% had cellulitis, 19% abscesses, 22% wound and 1% burns. Key endpoints are given in the following table. The % of CV patients with at least one treatment-related adverse event (AE) was similar for DLX (22.7%) compared with VAN/AZ (22.4%). There were 2 DLX and 5 VAN/ AZ-treated CV patients discontinued due to related AEs. The most frequent treatment-related AEs were gastrointestinal including diarrhea seen in 8.2% and 3.1% of DLX and VAN/AZ patients respectively, generally mild to moderate in nature with no cases of C. difficile diarrhea. There were no cardiac events or deaths attributed to either study drug.
Conclusion. In CV patients, fixed dose DLX monotherapy was comparable to VAN/AZ in treatment of ABSSSI based on the early objective and investigator assessed responses at FU and LFU. DLX was also comparable to VAN/AZ in treating patients with S. aureus. There were no cardiac events or deaths in either study group. DLX appears effective and well tolerated in CV patients with ABSSSI.
Disclosures. Background. Delafloxacin, a fluoroquinolone antibiotic with Gram-negative and Gram-positive activity including MRSA, was approved for treatment of ABSSSI. In a phase 3 ABSSSI trial, DLX was non-inferior to VAN/AZ in both objective and clinical response endpoints. Clinical signs and symptoms (S&S) and lesion size measurements also were evaluated in this trial.
Resolution of Signs and Symptoms (S&S) of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) With Delafloxacin (DLX) IV/Oral Therapy
Methods. A multicenter, double-blind trial of adults with ABSSSI patients randomized 1:1 to receive either DLX monotherapy 300mg q12h IV with switch to oral 450 mg q12h or vancomycin (VAN) 15 mg/kg (actual body weight) with aztreonam (AZ) for 5-14 days. AZ was discontinued once Gram-negative infection was excluded in the VAN arm. The presence or absence of clinical S&S were collected at each evaluation timepoint. Patients with complete resolution of S&S were classified as complete cures. Lesions were measured by digital planimetry. Patient-reported pain was recorded by numerical rating scale (NRS; 0=no pain, 10= worst pain). Assessments were completed at baseline, during and at end of treatment (EOT), at and Late Follow-up (LFU day 21-28).
Results. 850 patients were randomized in United States, Europe, Asia and Latin America. 63% were male with mean age 51 years. 48% had cellulitis, 25% abscesses, 26% wound and 1% burn infections. Baseline erythema and induration were reported in 100% and 93% of patients, respectively. Mean area of erythema and induration at baseline was 353 and 138 cm 2 respectively. Most common locations for lesions were lower extremities (56%) and upper extremities (24%). S. aureus was the most common isolate. Mean days of treatment was 7 days in either group. DLX and VAN/AZ patients had comparable impact on S&S with complete resolution in 42% vs. 45% at EOT, and 58% vs. 60% at FU, and 68% vs. 71% at LFU respectively. DLX was comparable to VAN/AZ in percent reduction in erythema over time (figure) . There was a mean reduction of 58% vs. 53% at 48-72 h, 90% vs. 87% at EOT, and 98% vs. 97% at LFU for DLX and VAN/AZ respectively (figure). Baseline mean pain scores were 7/10 with scores of ~1/10 at EOT and ~0.5/10 at FU for both treatment groups.
Conclusion. Treatment with DLX and VAN/AZ provided equally rapid improvement in clinical signs and symptoms in ABSSSI with comparable reductions in S&S, lesion size and pain score.
